My lab uses genetic approaches to understand and develop treatments for mitochondrial diseases. We develop the treatments in a translatable manner to directly benefit the patient population. The diseases that we are currently working on involve genes that are encoded in both the nuclear DNA and mitochondrial DNA, with neurological manifestations.
Morningside Graduate School of Biomedical Sciences
Elisabeth Chair for the Dean of Medicine
Penelope Booth Rockwell Chair in Biomedical Research
Focus: Adeno-associated virus vector mediated gene transfer for gene therapy, gene therapy of inherited neurodegenerative Canavan Disease
Dr. Esteves is a neuroscientist with interest in gene therapy to help treat neurodegenerative diseases.
China Pharmaceutical University, Clinical Pharmacy
Chinese Academy of Sciences, Neuropharmacology
We are looking for motivated postdoctoral researchers. Send in your application and get in touch today!
- AAV gene therapy for genetic diseases - Therapeutic genome editing - RNA-based approaches to treating genetic diseases - Interactions between AAV vector and host cell - AAV vector capsid engineering
Molecular therapy : the journal of the American Society of Gene Therapy
Ling Q. A "one size fits all" gene therapy for neurological disorders with mitochondrial dysfunction. Mol Ther. 2024 Jul 03; 32(7):2045-2046.
A "one size fits all" gene therapy for neurological disorders with mitochondrial dysfunction.
Ling Q, Herstine JA, Bradbury A, Gray SJ
Ling Q, Herstine JA, Bradbury A, Gray SJ. AAV-based in vivo gene therapy for neurological disorders. Nat Rev Drug Discov. 2023 10; 22(10):789-806.
AAV-based in vivo gene therapy for neurological disorders.
Molecular therapy. Methods & clinical development
Ling Q, Rioux M, Hu Y, Lee M, Gray SJ. Adeno-associated viral vector serotype 9-based gene replacement therapy for SURF1-related Leigh syndrome. Mol Ther Methods Clin Dev. 2021 Dec 10; 23:158-168.
Adeno-associated viral vector serotype 9-based gene replacement therapy for SURF1-related Leigh syndrome.
Ling QL, Murdoch E, Ruan KH. How can we address the controversies surrounding the use of NSAIDS in neurodegeneration? Future Med Chem. 2016 07; 8(11):1153-5.
How can we address the controversies surrounding the use of NSAIDS in neurodegeneration?
Ling QL, Akasaka H, Chen C, Haile CN, Winoske K, Ruan KH
Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology
Ling QL, Akasaka H, Chen C, Haile CN, Winoske K, Ruan KH. The Protective Effects of Up-Regulating Prostacyclin Biosynthesis on Neuron Survival in Hippocampus. J Neuroimmune Pharmacol. 2020 06; 15(2):292-308.
The Protective Effects of Up-Regulating Prostacyclin Biosynthesis on Neuron Survival in Hippocampus.
Ling QL, Mohite AJ, Murdoch E, Akasaka H, Li QY, So SP, Ruan KH
Ling QL, Mohite AJ, Murdoch E, Akasaka H, Li QY, So SP, Ruan KH. Creating a mouse model resistant to induced ischemic stroke and cardiovascular damage. Sci Rep. 2018 01 26; 8(1):1653.
Creating a mouse model resistant to induced ischemic stroke and cardiovascular damage.
Ling Q, Rioux M, Higgs H, Hu Y, Dwyer SE, Gray SJ
Ling Q, Rioux M, Higgs H, Hu Y, Dwyer SE, Gray SJ. Improved AAV9-based gene therapy design for SURF1-related Leigh syndrome with minimal toxicity. Mol Ther Methods Clin Dev. 2025 Sep 11; 33(3):101554.
Improved AAV9-based gene therapy design for SURF1-related Leigh syndrome with minimal toxicity.